T. Rowe Price reports 6.72M shares (8.0%) in CG Oncology

CG Oncology Inc disclosure: T. Rowe Price Investment Management, Inc. reports 6,720,389 shares of Common Stock, representing 8.0% of the class as of 03/31/2026.

Rhea-AI Filing Summary

CG Oncology Inc disclosure: T. Rowe Price Investment Management, Inc. reports 6,720,389 shares of Common Stock, representing 8.0% of the class as of 03/31/2026. The filing lists 6,459,822 shares of sole voting power and affirms that the filer denies beneficial ownership in the filing's declaration. The signature block is dated 05/15/2026.

Insights

Institutional Ownership Analyst

Large passive holding reported; filer disclaims beneficial ownership.

The filing shows 6,720,389 shares (8.0%) of Common Stock as of 03/31/2026, with 6,459,822 shares of sole voting power recorded. Schedule 13G is typically used by passive investors or reporting persons meeting specific thresholds.

Because the statement expressly denies beneficial ownership, the economic interest and control attribution are governed by the filer's internal claim; subsequent filings or amendments may clarify any voting or dispositive arrangements.

Compliance & Regulatory Specialist

Form type and declaration affect legal attribution and reporting obligations.

As a Schedule 13G filing, the report indicates a passive reporting status under the securities rules rather than an active acquisition disclosure. The document includes exact counts for voting and dispositive power, which are key for regulatory treatment.

If facts differ materially, the filer would typically amend the filing; the signature date is 05/15/2026, while the ownership figures are dated 03/31/2026.

Key Figures

Shares beneficially owned: 6,720,389 shares Percent of class: 8.0% Sole voting power: 6,459,822 shares +2 more

5 metrics

Shares beneficially owned 6,720,389 shares as of 03/31/2026

Percent of class 8.0% beneficial ownership percentage as reported

Sole voting power 6,459,822 shares number with sole power to vote

Sole dispositive power 6,720,389 shares number with sole power to dispose

CUSIP 156944100 CG Oncology Inc Common Stock identifier

Key Terms

Schedule 13G, beneficially owned, sole dispositive power

3 terms

Schedule 13G regulatory

"Item 1. (a) Name of issuer: CG ONCOLOGY INC"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Item 4. (a) Amount beneficially owned: 6720389"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Item 4. (c)(iii) Sole power to dispose or to direct the disposition of: 6720389"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Schedule 13G filed by T. Rowe Price for CGON show?

It reports 6,720,389 shares of Common Stock, representing 8.0% of the class as of 03/31/2026. The filing also lists voting and dispositive power figures and includes a declaratory denial of beneficial ownership.

Does the filing state who controls voting or disposition of the CGON shares?

Yes. The filing lists 6,459,822 shares as sole voting power and 6,720,389 shares as sole dispositive power. Those counts are reported in the ownership table dated 03/31/2026.

What is the significance of the filer's denial of beneficial ownership in the Schedule 13G?

The filer expressly denies beneficial ownership in the signature paragraph. This statement is a formal representation that affects how the holding is attributed for regulatory purposes under Schedule 13G reporting conventions.

When was the Schedule 13G signed for the CGON disclosure?

The signature block shows the filing was signed by Ellen York, Vice President, on 05/15/2026. The ownership figures are reported as of 03/31/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:06 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

CG ONCOLOGY INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

156944100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 156944100

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,459,822.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,720,389.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,720,389.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CG ONCOLOGY INC
(b)	Address of issuer's principal executive offices: 3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS, TX, 75247
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 156944100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6720389
(b)	Percent of class: 8.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6459822
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6720389
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026